Searched for
PHARMACEUTICAL NAMES
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalizing on growing demand as major pharmaceutic...- Quant Mid Cap Fund adds Adani Energy and 4 others, exits Paytm and 3 more stocks in MayQuant Mid Cap Fund, managed by Sandeep Tandon, has strategically adjusted its portfolio in May. The fund added Adani Energy and four other ...
- Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Light at the end of the tunnel? Gautam Shah sees Nifty eyeing 25,500, bets on smallcaps, pharma and Adani stocksIndian equities are nearing a crucial turning point, with market veteran Gautam Shah suggesting a shift in focus beyond benchmark indices. ...
- Why a Rs 72,000 crore fund manager refuses to chase defence rally nowICICI Prudential's Mittul Kalawadia advises caution on current market valuations. He notes that future growth is already factored into stoc...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- 5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
- NCLAT quashes Ligare Aviation's insolvency; loan from Religare Enterprises round-tripping of moneyThe National Company Law Appellate Tribunal has cancelled insolvency proceedings against Ligare Aviation. The tribunal found the National C...
- How an Australian connection helped Shaily Mehrotra build a Rs 1,500-crore Indian skincare brandA gap in science-backed skincare products in the Indian market prompted Shaily Mehrotra to start Fixderma, with an aim to solve common skin...
- Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyersAlkem Laboratories shares experienced significant block deals totaling Rs 930 crore. Promoter family entities divested shares to a group of...
- In the 1930s, rubber factory workers drank alcohol and suddenly felt sick. It wasn't just a workplace illness, it led to the discovery of Antabuse, helping millions quit drinkingAn accidental discovery in a rubber factory in the 1930s revealed that workers exposed to tetraethylthiuram disulfide experienced severe re...
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- 20 months of bearish markets: One additional letter that tells you which 'cheap' stocks are actually cheapMost investors live by one ratio. That ratio that tells them all they want to know – or should one say all they want to hear? They open a s...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Buy, Sell or Hold: Citi maintains buy on Eicher Motors; Goldman Sachs retains buy on Max HealthcareBrokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...
Load More
